Advances in biomarkers in multiple system atrophy.

Area of Science:

• Neurology
• Biomarker Discovery
• Diagnostic Technologies

Background:

• Multiple System Atrophy (MSA) diagnosis and monitoring face challenges.
• Current diagnostic methods lack sufficient sensitivity and specificity for early detection and progression tracking.
• There is a need for innovative biomarkers and technologies to improve patient outcomes.

Purpose of the Study:

• To highlight the potential of fluid and imaging biomarkers in revolutionizing MSA diagnosis and monitoring.
• To discuss advancements in diagnostic technologies for MSA.
• To emphasize the importance of a multi-dimensional biomarker system for enhanced MSA care.

Main Methods:

• Review of novel diagnostic technologies such as multiplex seeding aggregation assays (SAA) and advanced imaging techniques (18FDG-PET, SPECT).
• Discussion of fluid biomarkers including neurofilament light chain (NFL) and alpha-synuclein (α-synuclein) in cerebrospinal fluid (CSF) and blood.
• Exploration of challenges and limitations in current biomarker research and clinical application.

Main Results:

• Innovations in SAA and PET/SPECT imaging offer new avenues for early MSA detection and noninvasive monitoring.
• While NFL and α-synuclein show promise as diagnostic and surrogate markers, their clinical use is limited.
• Development of selective α-synuclein PET tracers is underway despite challenges in visualizing intracellular targets.

Conclusions:

• A multi-dimensional biomarker system, integrating multi-omics data, can maximize the power of contemporary diagnostics for MSA.
• Overcoming limitations such as high costs, lack of multicenter studies, and protocol standardization requires continued stakeholder collaboration.
• These advancements are crucial for improving illness identification, monitoring, and ultimately, patient outcomes in MSA.